

Monterrey, Mexico. April 18, 2018 - Alpek, S.A.B. de C.V. (BMV: ALPEK)

#### Alpek reports 1Q18 EBITDA of U.S. \$181 million

#### **Selected Financial Information**

(U.S. \$ Millions)

				(%) 1Q	18 vs.
	1Q18	4Q17	1Q17	4Q17	1Q17
Total Volume (ktons)	1,016	975	986	4	3
Polyester	787	752	759	5	4
Plastics & Chemicals	229	224	227	3	1
Consolidated Revenues	1,532	1,321	1,293	16	19
Polyester	1,109	933	916	19	21
Plastics & Chemicals	423	388	376	9	12
Consolidated EBITDA	181	141	158	29	15
Polyester	111	77	87	44	27
Plastics & Chemicals	69	64	70	9	(2)
Profit Attributable to Controlling Interest	82	(30)	87	372	(5)
CAPEX and Acquisitions	56	30	76	87	(26)
Net Debt	1,270	1,262	1,175	1	8
Net Debt/LTM EBITDA <sup>(1)</sup>	3.1	3.3	1.8		
Interest Coverage <sup>(1)</sup>	4.8	4.8	10.0		
(1) Times: Last 12 months					

<sup>(1)</sup> Times: Last 12 months

#### **Operating & Financial Highlights (1Q18)**

Alpek	<ul> <li>1Q18 Consolidated EBITDA of U.S. \$181 million, including a U.S. \$16 million non-cash inventory gain and U.S. \$5 million non-recurring legal fees/expenses</li> <li>Process to finalize cogeneration power plant sale in Mexico is ongoing</li> <li>Signed 3-year credit of up to U.S. \$710 million with 18-month availability period</li> </ul>
Polyester	<ul> <li>JV among Alpek, Indorama and Far Eastern to acquire Corpus Christi project from M&amp;G USA</li> <li>Normalized M&amp;G Mexico operations in 1Q18</li> <li>Engaged in the confirmation of final conditions required to close PetroquímicaSuape and Citepe acquisition</li> </ul>
Plastics & Chemicals (P&C)	<ul> <li>1Q18 P&amp;C EBITDA of U.S. \$69 million, including a U.S. \$1 million non-cash inventory gain</li> <li>P&amp;C results benefited from a spike in polypropylene (PP) reference prices amid tight supply caused mainly by U.S. propylene plant outages and startup delays</li> </ul>

This release contains forward-looking information based on numerous variables and assumptions that are inherently uncertain. They involve judgments with respect to, among other things, future economic, competitive and financial market conditions and future business decisions, all of which are difficult or impossible to predict accurately. Accordingly, results could vary from those set forth in this release. The report presents unaudited financial information based on International Financial Reporting Standards (IFRS). Figures are stated in nominal Mexican pesos (\$) and in current U.S. Dollars (U.S. \$), as indicated. Where applicable, peso amounts were translated into U.S. Dollars using the average exchange rate of the months during which operations were recorded. Financial ratios are calculated in U.S. Dollars. Due to the rounding up of figures, small differences may occur when calculating percent changes from one period to the other.



#### Message from the CEO

Alpek's first quarter 2018 consolidated EBITDA was up 15% versus 1Q17 and 29% higher than 4Q17 driven mainly by Polyester segment performance. Results reflect a better-than-expected start this year for several relevant underlying external variables, including higher oil prices, global polyester margin recovery and higher M&G Polímeros México, S.A. de C.V. (M&G Mexico) PET operating rates, among others.

The average price of Brent crude oil was U.S. \$67 per barrel in 1Q18, up 9% versus 4Q17 and U.S. \$10 per barrel higher than Alpek's 2018 Guidance. Similarly, the average U.S. paraxylene and propylene contract prices increased 8% quarter-on-quarter. Higher feedstock prices resulted in a U.S. \$16 million non-cash inventory gain during the first quarter.

1Q18 Polyester segment EBITDA was U.S. \$111 million, including a U.S. \$15 million non-cash inventory gain and U.S. \$5 million in non-recurring legal fees/expenses. Adjusting for these two items, Comparable Polyester EBITDA was U.S. \$102 million, up 48% and 54% when compared with 1Q17 and 4Q17, respectively. Normalized M&G Mexico PET operations and polyester margin recovery amid a rising feedstock price environment contributed to EBITDA growth.

M&G Mexico reached normalized PET production levels supported by Alpek through secured financing while a definitive restructuring plan is presented. Alpek's priorities in M&G Mexico's restructuring process are: i) maximizing the recovery of its claims and ii) maintaining its PTA supply to the restructured entity.

The restructuring process associated to M&G USA's Corpus Christi project advanced in 1Q18. Corpus Christi Polymers LLC (CC Polymers), a newly formed joint venture between Alpek, Indorama and Far Eastern, received court approval to acquire the Corpus Christi project and other related assets from M&G USA. The approved terms imply a total value of U.S. \$1.169 billion in cash and other capital contributions. Each JV partner will contribute up to U.S. \$390 million, subject to final adjustments. Alpek's portion will be reduced by a U.S. \$200 million non-cash contribution associated to its second lien on the Corpus Christi project. In accordance with IFRS, Alpek may recognize its non-cash contribution as a partial recovery of previous asset impairments upon closing of the transaction, which is subject to approval by governmental authorities.

Alpek, Indorama and Far Eastern will each have the right to receive one-third of the PTA and PET produced at the Corpus Christi project upon completion. CC Polymers will obtain additional resources from the three JV partners to resume the plant's construction upon closing of the transaction. A cost estimation and timeline for the project will be announced in due course.

Other relevant events include: i) the acquisition in Brazil of Companhia Petroquímica de Pernambuco (PetroquímicaSuape) and Companhia Integrada Têxtil de Pernambuco (Citepe) from Petrobras, ii) the sale of our two cogeneration power plants, and iii) the PET antidumping cases in the United States and Canada.

The transaction with Petrobras received the required regulatory approval from the CADE Court in Brazil during 1Q18. Since then, Alpek has worked closely with Petrobras to ensure that all agreed upon conditions are fulfilled prior to closing, which is expected before the end of the second quarter.

The process to finalize the sale of our two cogeneration power plants in Mexico is moving forward as the 350 MW Altamira plant's construction is on track to be completed before year-end. However, issues in the implementation of regulatory changes in Mexican power tariffs have weighed on timing.



Regarding the PET antidumping cases, the United States Department of Commerce (USDOC) is conducting its investigations on PET imports from Brazil, Indonesia, Korea, Pakistan and Taiwan. The USDOC is expected to issue its preliminary determinations and, if applicable, impose provisional duties in 2Q18. Conversely, the Canadian International Trade Tribunal ruled that PET resin imports from China, India, Oman and Pakistan have not caused injury and are not threatening to cause injury to the sole Canadian producer. This ruling has been appealed.

1Q18 Capex was U.S. \$56 million as progress continued on the investment front. The initial contribution to CC Polymers for the acquisition of the Corpus Christi project, plus the investment in the Altamira power cogeneration facility accounted for 70% of Alpek's first quarter Capex.

Alpek maintains a solid financial position supported by a strong balance sheet and liquidity. At the close of 1Q18, Net Debt totaled U.S. \$1.270 billion and Net Debt to EBITDA was 3.1 times or 2.4 times when adjusted for the U.S. -\$113 million M&G A/R provision that affected EBITDA in 3Q17. The balance of Cash and Cash Equivalents was U.S. \$440 million in 1Q18.

Moreover, Alpek signed a 3-year, dollar-denominated, Senior Unsecured Credit Agreement of up to U.S. \$710 million with The Bank of Tokyo-Mitsubishi UFJ, Ltd., Citigroup Global Markets Inc., HSBC México, S.A., Institución de Banca Múltiple, Grupo Financiero HSBC and JPMorgan Chase Bank, N.A. The loan has an 18-month availability period and can be prepaid at any time in whole or in part without premium or penalty. Net proceeds from the potential sale of the two power cogeneration plants in Mexico would be used to pay down the loan's balance at that time. This provides Alpek with additional financial flexibility to refinance existing short-term debt and temporarily finance the acquisition of PetroquímicaSuape, Citepe and the Corpus Christi project.

The optimistic outlook we anticipated for the year was reaffirmed by a strong start in 1Q18. First quarter results are supportive for 2018 EBITDA to be higher than our U.S. \$ 569 million Guidance. This will be taken into consideration when updating our 2018 Guidance in 2Q18 to include pending non-recurrent transactions such as the acquisition in Brazil and the potential sale of the two power cogeneration plants in Mexico.



#### **Results by Business Segment**

#### **Polyester**

(Purified Terephthalic Acid (PTA), Polyethylene Terephthalate (PET), Polyester fibers – 72% of Alpek's Net Sales)

Alpek's first quarter 2018 Polyester revenues were up 21% year-on-year and 19% quarter-on-quarter, driven by a combination of higher volume and average prices. Average 1Q18 Polyester prices increased 17% and 14% when compared with 1Q17 and 4Q17, respectively, reflecting the rise in feedstock prices such as paraxylene (Px) and monoethylene glycol (MEG). The average U.S. contract Px price reached its highest level since 2Q15.

1Q18 Polyester volume was up 4% and 5% when compared with 1Q17 and 4Q17, respectively. Normalized operations at M&G Mexico and robust demand amid a rising feedstock price environment contributed to Polyester volume growth.

First quarter 2018 segment EBITDA was U.S. \$111 million, including a U.S. \$15 million non-cash inventory gain and U.S. \$5 million in non-recurring legal fees/expenses. Adjusting for these two items, Comparable 1Q18 Polyester EBITDA was U.S. \$102 million, up 48% and 54% when compared to 1Q17 and 4Q17, respectively. Global polyester margins continued to recover in 1Q18 from multi-year lows. The reference PTA and PET margins in Asia reached their highest level since 2011.

#### Plastics & Chemicals (P&C)

(Polypropylene (PP), Expandable Polystyrene (EPS), Caprolactam (CPL), Other products – 28% of Alpek's Net Sales)

1Q18 P&C revenue increased 12% year-on-year and 9% quarter-on-quarter mainly due to higher average prices. Average first quarter 2018 P&C prices were up 11% and 6% when compared with 1Q17 and 4Q17, respectively. Propylene and styrene prices posted a monthly spike in 1Q18.

First quarter 2018 P&C volume was up 1% versus 1Q17 as growth in EPS was partially offset by other P&C products. When compared to 4Q17, P&C volume increased 3% mainly driven by PP.

Segment EBITDA was U.S. \$69 million in 1Q18, including a U.S. \$1 million non-cash inventory gain. Adjusting for the inventory gain, Comparable 1Q18 P&C EBITDA was up 9% and 17% when compared with 1Q17 and 4Q17, respectively, supported by higher PP margins. PP benefited from a temporary spike in prices amid tight supply caused mainly by U.S. propylene plant outages and startup delays.



#### **Consolidated Financial Results**

**Net Sales:** Net Sales for the first quarter totaled U.S. \$1.532 billion, up 19% year-on-year and 16% quarter-on-quarter, mainly due to higher average consolidated prices in both business segments. Average 1Q18 consolidated prices increased 15% and 11% when compared with 1Q17 and 4Q17, respectively, reflecting the rise in oil and feedstock prices. 1Q18 consolidated volume was up 3% and 4% year-on-year and quarter-on-quarter, respectively, supported by growth in Polyester and P&C.

**EBITDA:** 1Q18 EBITDA was U.S. \$181 million, including a U.S. \$16 million non-cash inventory gain and U.S. \$5 million in non-recurring legal fees/expenses. Adjusting for these two items, Comparable Consolidated EBITDA was U.S. \$170 million, U.S. \$124 million and U.S. \$131 million in 1Q18, 4Q17 and 1Q17 respectively. Both business segments posted better-than-expected performance supported by higher oil prices, sustained polyester margin recovery and normalized operations at M&G Mexico, among others.

**Profit (Loss) Attributable to Controlling Interest:** Profit Attributable to Controlling Interest for the first quarter of 2018 was U.S. \$82 million, compared to U.S. \$87 million and U.S. \$30 million in 1Q17 and 4Q17, respectively. 1Q18 Profit Attributable to Controlling Interest was 5% lower than 1Q17 which benefited from a higher non-cash Fx gain.

**Capital Expenditures and Acquisitions (Capex):** 1Q18 Capex was U.S. \$56 million, compared to U.S. \$76 million and U.S. \$30 million in 1Q17 and 4Q17 respectively. The majority of these funds were invested in the construction of the Altamira power cogeneration facility and the initial contribution to CC Polymers for the acquisition of the Corpus Christi project.

**Net Debt:** Consolidated Net Debt as of March 31, 2018 was U.S. \$1.270 billion, up 8% and 1% versus 1Q17 and 4Q17, respectively. On an absolute basis, Net Debt increased U.S. \$7 million year-to-date. As of March 31, 2018, Gross Debt was U.S. \$1.709 billion and Cash totaled U.S. \$440 million. Financial ratios at the close of 1Q18 were: Net Debt to EBITDA of 3.1 times and Interest Coverage of 4.8 times. Adjusting for the U.S. -\$113 million M&G A/R provision in 3Q17, Net Debt to EBITDA was 2.4 times and Interest Coverage was 6.1 times.



#### **Appendix A - Tables**

#### TABLE 1 | VOLUME (KTONS)

				(%) 1Q18 vs.	
	1Q18	4Q17	1Q17	4Q17	1Q17
Total Volume	1,016	975	986	4	3
Polyester	787	752	759	5	4
Plastics and Chemicals	229	224	227	3	1

#### TABLE 2 | PRICE CHANGES (%)

(%) 1Q18 vs. 4Q17 1Q17 Polyester Avg. Ps. Prices 13 8 Avg. U.S. \$ Prices 14 17 **Plastics and Chemicals** Avg. Ps. Prices 5 3 Avg. U.S. \$ Prices 6 11 Total Avg. Ps. Prices 10 6 Avg. U.S. \$ Prices 11 15

#### TABLE 3 | INCOME STATEMENT (U.S. \$ Millions)

				(%) 1Q18 vs.	
	1Q18	4Q17	1Q17	4Q17	1Q17
Total Revenues	1,532	1,321	1,293	16	19
Gross Profit	203	162	171	25	18
Operating expenses and others	(59)	(52)	(48)	(13)	(23)
Operating income	144	110	123	30	17
Financial result, net	(5)	(68)	17	93	(129)
Equity in income of assoc. and JV	-	-	-	-	-
Income Tax	(35)	(62)	(34)	43	(5)
Consolidated net income	103	(20)	106	613	(3)
Controlling Interest	82	(30)	87	372	(5)



## TABLE 4 | REVENUES

				(%) 1Q18 vs	
	1Q18	4Q17	<b>1Q17</b>	4Q17	1Q17
Total Revenues					
Ps. Millions	28,746	25,010	26,339	15	9
U.S. \$ Millions	1,532	1,321	1,293	16	19
Domestic Revenues					
Ps. Millions	9,061	8,166	9,632	11	(6)
U.S. \$ Millions	483	431	473	12	2
Foreign Revenues					
Ps. Millions	19,685	16,844	16,707	17	18
U.S. \$ Millions	1,049	890	820	18	28
Foreign / Total (%)	68	67	63		

## TABLE 5 | OPERATING INCOME AND EBITDA

				(%) 1Q:	18 vs.
	1Q18	4Q17	1Q17	4Q17	1Q17
Operating Income					
Ps. Millions	2,695	2,084	2,535	29	6
U.S. \$ Millions	144	110	123	30	17
EBITDA					
Ps. Millions	3,391	2,660	3,241	27	5
U.S. \$ Millions	181	141	158	29	15

## TABLE 6 | COMPARABLE EBITDA

					(%) 1Q:	18 vs.
1Q18	4Q17	1Q17	4Q17	1Q17		
3,391	2,660	3,241	27	5		
181	141	158	29	15		
(196)	(309)	(550)	37	64		
(10)	(16)	(26)	37	61		
3,195	2,350	2,691	36	19		
170	124	131	37	30		
	3,391 181 (196) (10) 3,195 170	3,391 2,660 181 141 (196) (309) (10) (16) 3,195 2,350 170 124	3,391 2,660 3,241 181 141 158  (196) (309) (550) (10) (16) (26)  3,195 2,350 2,691	3,391 2,660 3,241 27 181 141 158 29  (196) (309) (550) 37 (10) (16) (26) 37  3,195 2,350 2,691 36 170 124 131 37		

<sup>\*</sup>Adjustments: Inventory and non-operating, one-time (gains) losses





#### **TABLE 7** | **FINANCIAL RESULT, NET (U.S. \$ Millions)**

				(%) 1Q:	18 vs.
	1Q18	4Q17	1Q17	4Q17	1Q17
Financial Expenses	(23)	(23)	(18)	-	(31)
Financial Income	6	2	4	213	58
Financial Expenses, Net	(17)	(21)	(14)	18	(24)
Fx Gains (Losses)	13	(47)	31	127	(59)
Financial Result, Net	(5)	(68)	17	93	(129)

## TABLE 8 | NET INCOME (U.S. \$ Millions)

				(%) 1Q1	18 vs.
	1Q18	4Q17	1Q17	4Q17	1Q17
Consolidated Net Income	103	(20)	106	613	(3)
Non-Controlling Interest	21	10	19	103	9
Controlling Interest	82	(30)	87	372	(5)
Earnings per Share (U.S. Dollars)	0.04	(0.01)	0.04	372	(5)
Avg. Outstanding Shares (Millions)*	2,117	2,117	2,117		

<sup>\*</sup> The same number of equivalent shares are considered in the periods presented

## TABLE 9 | CASH FLOW (U.S. \$ Millions)

				(%) 1Q:	18 vs.
	1Q18	4Q17	1Q17	4Q17	1Q17
EBITDA	181	141	158	29	15
Net Working Capital & Others	(85)	(37)	(64)	(127)	(31)
Capital Expenditures & Acq.	(56)	(30)	(76)	(87)	26
Financial Expenses	(22)	(22)	(16)	(1)	(39)
Income tax	(7)	(9)	(27)	20	72
Dividends	-	(7)	(88)	100	100
Payment affiliated companies	-	-	-	-	_
Other Sources / Uses	(18)	(105)	(20)	83	12
Decrease (Increase) in Net Debt	(7)	(70)	(134)	90	95



## TABLE 10 | STATEMENT OF FINANCIAL POSITION & FINANCIAL RATIOS (U.S. \$ Millions)

				(%) 1Q:	18 vs.
_	1Q18	4Q17	1Q17	4Q17	1Q17
Assets					
Cash and cash equivalents	440	484	126	(9)	250
Trade accounts receivable	694	544	582	28	19
Inventories	893	829	807	8	11
Other current assets	275	280	271	(2)	1
Total current assets	2,302	2,138	1,786	8	29
Investment in associates and others	69	33	29	109	136
Property, plant and equipment, net	2,108	2,105	2,028	-	4
Goodwill and intangible assets, net	203	206	571	(2)	(64)
Other non-current assets	307	270	227	14	35
Total assets	4,989	4,752	4,640	5	8
Liabilities & stockholders' equity					
Debt	361	375	278	(4)	30
Suppliers	979	874	692	12	42
Other current liabilities	230	170	171	35	34
Total current liabilities	1,570	1,420	1,141	11	38
Debt (include debt issuance cost)	1,343	1,366	1,017	(2)	32
Employees' benefits	54	54	60	1	(10)
Other long term liabilities	297	308	372	(3)	(20)
Total liabilities	3,264	3,147	2,590	4	26
Total stockholders' equity	1,725	1,604	2,050	7	(16)
Total liabilities & stockholders' equity	4,989	4,752	4,640	5	8
Net Debt	1,270	1,262	1,175	1	8
Net Debt/EBITDA*	3.1	3.3	1.8		
Interest Coverage*	4.8	4.8	10.0		
	7.0	7.0	10.0		

<sup>\*</sup> Times: last 12 months





## **Polyester**

## TABLE 11 | REVENUES

				(%) 1Q:	18 vs.
	1Q18	4Q17	1Q17	4Q17	1Q17
Total Revenues					
Ps. Millions	20,811	17,668	18,670	18	11
U.S. \$ Millions	1,109	933	916	19	21
Domestic Revenues					
Ps. Millions	4,223	3,679	5,006	15	(16)
U.S. \$ Millions	225	194	246	16	(8)
Foreign Revenues					
Ps. Millions	16,588	13,989	13,663	19	21
U.S. \$ Millions	884	739	670	20	32
Foreign / Total (%)	80	79	73		

## TABLE 12 | OPERATING INCOME AND EBITDA

				(%) 1Q18 vs.	
	1Q18	4Q17	1Q17	4Q17	1Q17
Operating Income					
Ps. Millions	1,538	1,022	1,253	50	23
U.S. \$ Millions	82	54	61	52	35
EBITDA					
Ps. Millions	2,091	1,467	1,794	43	17
U.S. \$ Millions	111	77	87	44	27

## TABLE 13 | COMPARABLE EBITDA

			(%) 1Q18 vs.	
1Q18	<b>4Q17</b>	1Q17	4Q17	1Q17
2,091	1,467	1,794	43	17
111	77	87	44	27
(185)	(215)	(395)	14	53
(10)	(11)	(19)	13	48
1,905	1,252	1,399	52	36
102	66	69	54	48
	2,091 111 (185) (10)	2,091 1,467 111 77 (185) (215) (10) (11) 1,905 1,252	2,091 1,467 1,794 111 77 87 (185) (215) (395) (10) (11) (19) 1,905 1,252 1,399	1Q18     4Q17     1Q17     4Q17       2,091     1,467     1,794     43       111     77     87     44       (185)     (215)     (395)     14       (10)     (11)     (19)     13       1,905     1,252     1,399     52

<sup>\*</sup>Adjustments: Inventory and non-operating, one-time (gains) losses





#### **Plastics & Chemicals**

#### TABLE 14 | REVENUES

				(%) 1Q18 vs.	
	1Q18	4Q17	1Q17	4Q17	1Q17
Total Revenues					
Ps. Millions	7,934	7,342	7,670	8	3
U.S. \$ Millions	423	388	376	9	12
Domestic Revenues					
Ps. Millions	4,838	4,487	4,626	8	5
U.S. \$ Millions	258	237	227	9	13
Foreign Revenues					
Ps. Millions	3,096	2,855	3,044	8	2
U.S. \$ Millions	165	151	149	9	11
Foreign / Total (%)	39	39	40		

#### TABLE 15 OPERATING INCOME AND EBITDA

				(%) 1Q18 vs.	
	1Q18	4Q17	1Q17	4Q17	1Q17
Operating Income					
Ps. Millions	1,158	1,071	1,282	8	(10)
U.S. \$ Millions	62	57	62	9	(1)
EBITDA					
Ps. Millions	1,302	1,203	1,447	8	(10)
U.S. \$ Millions	69	64	70	9	(2)

## TABLE 16 | COMPARABLE EBITDA

				(%) 1Q18 vs.	
	1Q18	4Q17	<b>1Q17</b>	4Q17	1Q17
EBITDA			-		
Ps. Millions	1,302	1,203	1,447	8	(10)
U.S. \$ Millions	69	64	70	9	(2)
Adjustments*					
Ps. Millions	(11)	(94)	(154)	89	93
U.S. \$ Millions	(1)	(5)	(8)	89	93
Comparable EBITDA					
Ps. Millions	1,291	1,108	1,293	17	-
U.S. \$ Millions	69	59	63	17	9
*Adjustments: Inventory and non-ope	rating, one-time (gain	s) losses			





# **Appendix B – Financial Statements**

#### **ALPEK, S.A.B. DE C.V. and Subsidiaries**

#### STATEMENT OF FINANCIAL POSITION

Information in Millions of Mexican Pesos				(0() 8.6	40
	Mar 18	Dec 17	Mar 17	(%) Ma Dec 17	ır 18 vs. Mar 17
ASSETS	IVIGI 10	Dec 17	IVIGI 17	Dec 17	Widi 17
CURRENT ASSETS:					
Cash and cash equivalents	7,354	8,795	2,362	(16)	211
Restricted cash	710	763	2	(7)	33,662
Trade accounts receivable	12,740	10,739	10,939	19	16
Other accounts and notes receivable	3,798	4,152	3,503	(9)	8
Inventories	16,374	16,364	15,187	O	8
Other current assets	1,247	1,379	1,597	(10)	(22)
Total current assets	42,223	42,192	33,590	0	26
Investment in associates and others	1,263	650	547	94	131
Property, plant and equipment, net	38,670	41,535	38,136	(7)	1
Goodwill and intangible assets, net	3,719	4,065	10,738	(9)	(65)
Other non-current assets	5,639	5,336	4,269	6	32
Total assets	91,514	93,778	87,280	(2)	5
LIABILITIES AND STOCKHOLDER'S EQUITY					
CURRENT LIABILITIES:					
Debt	6,621	7,408	5,228	(11)	27
Suppliers	17,961	17,255	13,009	4	38
Other current liabilities	4,212	3,356	3,216	26	31
Total current liabilities	28,794	28,019	21,453	3	34
NON-CURRENT LIABILITIES:					
Debt (include debt issuance cost)	24,639	26,958	19,134	(9)	29
Deferred income taxes	4,142	4,403	5,410	(6)	(23)
Other non-current liabilities	1,310	1,673	1,592	(22)	(18)
Employee benefits	992	1,061	1,127	(7)	(12
Total liabilities	59,877	62,114	48,716	(4)	23
STOCKHOLDERS' EQUITY:					
Controlling interest:					
Capital stock	6,050	6,048	6,048	0	0
Share premium	9,071	9,071	9,071	-	-
Contributed capital	15,121	15,119	15,119	0	0
Earned surplus	11,719	11,797	19,155	(1)	(39)
Total controlling interest	26,840	26,916	34,274	(0)	(22)
Non-controlling interest	4,797	4,748	4,290	1	12
Total stockholders' equity	31,637	31,664	38,564	(0)	(18)
Total liabilities and stockholders' equity	91,514	93,778	87,280	(2)	5



#### ALPEK, S.A.B. DE C.V. y Subsidiarias

#### **ESTADO DE RESULTADOS**

Información en Millones de Pesos mexicanos						
					1T18 vs.(%)	
	1T18	4T17	1T17	4T17	1T17	
Ingresos	28,746	25,010	26,339	15	9	
Nacionales	9,061	8,166	9,632	11	(6)	
Exportación	19,685	16,844	16,707	17	18	
Costo de ventas	(24,943)	(21,941)	(22,826)	(14)	(9)	
Utilidad bruta	3,803	3,069	3,513	24	8	
Gastos de operación y otros	(1,108)	(985)	(978)	(12)	(13)	
Utilidad de operación	2,695	2,084	2,535	29	6	
Resultado Financiero, neto	(84)	(1,296)	317	94	(126)	
Participación en resultados de asociadas y negocios conjuntos	(9)	-	(2)	(3,924)	(250)	
Utilidad (pérdida) antes de impuestos	2,602	788	2,850	230	(9)	
Impuestos a la utilidad	(664)	(1,173)	(693)	43	4	
Utilidad neta consolidada	1,938	(385)	2,157	603	(10)	
Utilidad atribuible a Participación controladora	1,550	(577)	1,769	369	(12)	
Utilidad atribuible a Participación no controladora	388	192	388	102	_	